Fansidar (pyrimethamine and sulfadoxine)

Phase 1Small molecule

NNational Institute of Allergy and Infectious Diseases (NIAID)

Fansidar (pyrimethamine and sulfadoxine) is one of 6 small molecule programs targeting Lymphoproliferative Syndrome. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoproliferative SyndromeActive, not recruiting

Lymphoproliferative SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

5 competitors in Lymphoproliferative Syndrome

#DrugCompanyPhaseTrials

Arava

Depakote

1 3

Rituxan

Roche

Phase 2

—4

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 1

1 5

Soquelitinib

CCorvus Pharmaceuticals, Inc.

Phase 2

1 6

Fansidar (pyrimethamine and sulfadoxine)

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lymphoproliferative Syndrome1 trial

Pyrimethamine and Sulfadoxine for Treatment of Autoimmune Lymphoproliferative Syndrome

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00013689·8 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fansidar (pyrimethamine and sulfadoxine). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fansidar (pyrimethamine and sulfadoxine) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fansidar (pyrimethamine and sulfadoxine). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Fansidar (pyrimethamine and sulfadoxine)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lymphoproliferative Syndrome1 trial

References

Drug Info

Quick Facts

Related News